RxDoctor Payments Data

Francis Alcedo, MD

Internal Medicine · Trumbull, CTNPI 1225091713

Payments from drug & device makers

$175in general payments, 2019–2025

Across 11 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$88
  • Amgen$28
  • AbbVie$19
  • Sunovion Pharmaceuticals Inc.$15
  • Johnson & Johnson$14
  • AstraZeneca$12

What the payments were for

  • Food & beverage$14884%
  • Education$2816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$175 in reported general payments places this provider in the 55th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$107,580
Medicare patients
187
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate88$116,430
EliquisApixaban89$89,379
TradjentaLinagliptin57$60,747
JardianceEmpagliflozin55$52,709
OzempicSemaglutide43$42,986
FarxigaDapagliflozin Propanediol23$31,942
XareltoRivaroxaban14$20,351
Breo ElliptaFluticasone/Vilanterol45$19,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,519
MyrbetriqMirabegron13$11,279
Tresiba Flextouch U-100Insulin Degludec11$5,138
Atorvastatin Calcium646$5,098
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$4,496
SymbicortBudesonide/Formoterol Fumarate12$4,235
Albuterol Sulfate HfaAlbuterol Sulfate195$4,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$42,98643 claims
AstraZenecaFarxiga, Symbicort$12$36,17735 claims
Johnson & JohnsonXarelto$14$20,35114 claims
AbbVieSynthroid$19$2,88538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →